A detailed history of Jpmorgan Chase & CO transactions in Bio N Tech Se stock. As of the latest transaction made, Jpmorgan Chase & CO holds 26,703 shares of BNTX stock, worth $2.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,703
Previous 49,719 46.29%
Holding current value
$2.89 Million
Previous $4 Million 20.63%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$78.36 - $124.66 $1.8 Million - $2.87 Million
-23,016 Reduced 46.29%
26,703 $3.17 Million
Q2 2024

Aug 12, 2024

BUY
$80.36 - $102.87 $3.39 Million - $4.33 Million
42,123 Added 554.54%
49,719 $4 Million
Q1 2024

May 10, 2024

SELL
$88.96 - $112.35 $20,549 - $25,952
-231 Reduced 2.95%
7,596 $700,000
Q4 2023

Feb 12, 2024

BUY
$90.91 - $112.75 $641,551 - $795,676
7,057 Added 916.49%
7,827 $826,000
Q3 2023

Nov 14, 2023

BUY
$98.5 - $125.08 $15,957 - $20,262
162 Added 26.64%
770 $83,000
Q2 2023

Aug 11, 2023

SELL
$102.58 - $129.66 $2.5 Million - $3.16 Million
-24,347 Reduced 97.56%
608 $65,000
Q1 2023

May 11, 2023

SELL
$122.57 - $153.67 $248,694 - $311,796
-2,029 Reduced 7.52%
24,955 $3.11 Million
Q4 2022

Feb 13, 2023

BUY
$118.43 - $186.05 $1.35 Million - $2.11 Million
11,365 Added 72.76%
26,984 $4.05 Million
Q3 2022

Nov 14, 2022

SELL
$127.65 - $183.11 $367,887 - $527,723
-2,882 Reduced 15.58%
15,619 $2.11 Million
Q2 2022

Aug 11, 2022

SELL
$123.25 - $186.24 $210,880 - $318,656
-1,711 Reduced 8.47%
18,501 $2.76 Million
Q1 2022

May 11, 2022

SELL
$126.25 - $231.85 $2.39 Million - $4.38 Million
-18,902 Reduced 48.33%
20,212 $3.45 Million
Q4 2021

Feb 10, 2022

BUY
$216.64 - $362.52 $672,233 - $1.12 Million
3,103 Added 8.62%
39,114 $10.1 Million
Q3 2021

Nov 12, 2021

BUY
$205.93 - $447.23 $7.42 Million - $16.1 Million
36,011 New
36,011 $9.83 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $26.3B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.